AAV BBP-631 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 81 | 先天性副腎皮質酵素欠損症 | 1 |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 88 / 薬物数 : 90 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04783181 (ClinicalTrials.gov) | July 1, 2021 | 1/3/2021 | A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene | Congenital Adrenal Hyperplasia | Biological: AAV BBP-631 | Adrenas Therapeutics Inc | NULL | Recruiting | 18 Years | N/A | All | 25 | Phase 1/Phase 2 | United States;Australia |